Product Name | 5(6) - CR6G, SE5 - (and - 6) - Carboxyrhodamine 6G, succinimidyl ester; 5(6) - CR6G, NHS ester |
Size | 10 mg |
Catalog # | AS-81104 |
US$ | $164 |
Purity | >90% |
5(6)-CR6G, SE is the amine-reactive form of 5(6)-CR6G. In general, rhodamine 6G conjugates have higher fluorescence quantum yields than tetramethylrhodamine conjugates, as well as good photostability. The excitation and emission peaks of rhodamine 6G conjugates falling between those of fluorescein and tetramethylrhodamine provide another color choice for the multicolor imaging applications. Additionally the absorption maxima of CR6G conjugates match well with the 514 nm spectral line of the argon-ion laser. | |
Detailed Information | DatasheetMaterial Safety Data Sheets (MSDS) |
Storage | -20°C desiccated and protected from light |
References | 1. Hung SC, et al. Anal Biochem 252, 78-88; (1997).2. Hung SC, et al. Anal Biochem 238, 165-70; (1996). |
Molecular Weight | 555.58 |
Molecular Formula | C31H29N3O7 |
Spectral Properties | Abs/Em = 522/550 nm |
Solvent System | DMF or DMSO |
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
)懂得一些道理或知识.
让世界充满爱不仅是付出,还可以是回报,回报你所关爱的人.
我记得有首歌曲,它的意思是爸爸妈妈辛苦了一天,回到家,帮他们拿拖鞋,帮他们倒杯茶,这是感
恩.老师批改作业累了,可以给他们捶捶背,当学习获得了一定的成功,老师会感到欣慰,这是感恩.当
同学遭遇困难时,你可以去用尽全力地安慰帮助他(她),使他(她)能够解决困难,克服困难,变得快
乐.这也是感恩.
B、是重要的储能物质,磷脂为构成生物膜的重要成分,固醇为动物细胞膜的构成物质及形成激素等,B错误;
C、蛋白质是细胞代谢的主要结构物质,糖类是细胞代谢的主要能源物质C错误;
D、ATP的结构简式是 A-P~P~P,其中A代表腺苷,腺苷是构成ATP的重要部分,D正确.
故选:D.
第一类激素作用在靶细胞表面,并不进入细胞内部,而是与细胞膜表面特异的受体结合.这种结合使腺苷酸环化酶激活产生cAMP(一种第二信使),cAMP再去激活细胞内的一些特定系列的酶,从而引起各种生理效应.这是由E.W.Sutherland于1965年提出来的第二信使假说
第二类激素由于是脂溶性的小分子.能直接进入靶细胞,与靶细胞的细胞质中的受体分子结合成"激素-受体复合物",在一定条件下穿过核膜进入核内,与染色质上的一种酸性蛋白质相互作用,促进DNA样板转录相应的mRNA.
mRNA扩散出核膜进入细胞质,导致某种蛋白质(酶)的合成,从而引起这种激素的生理效应.
http://care.diabetesjournals.org/cgi/content/abstract/31/8/1479
OBJECTIVE—Hyperglycemiaisariskfactorformicrovascularcomplicationsandmayincreasetheriskofcardiovasculardiseaseinpatientswithtype2diabetes.ThisstudytestedtheLDLcholesterol–loweringagentcolesevelamHCl(colesevelam)asapotentialnoveltreatmentforimprovingglycemiccontrolinpatientswithtype2diabetesonsulfonylurea-basedtherapy.
RESEARCHDESIGNANDMETHODS—A26-week,randomized,double-blind,placebo-controlled,parallel-group,multicenterstudywascarriedoutbetweenAugust2004andAugust2006toevaluatetheefficacyandsafetyofcolesevelamforreducingA1Cinadultswithtype2diabeteswhoseglycemiccontrolwasinadequate(A1C7.5–9.5%)withexistingsulfonylureamonotherapyorsulfonylureaincombinationwithadditionaloralanti-diabetesagents.Intotal,461patientswererandomized(230givencolesevelam3.75g/dayand231givenplacebo).Theprimaryefficacymeasurementwasmeanplacebo-correctedchangeinA1Cfrombaselinetoweek26intheintent-to-treatpopulation(lastobservationcarriedforward).
RESULTS—Theleastsquares(LS)meanchangeinA1Cfrombaselinetoweek26was–0.32%inthecolesevelamgroupand+0.23%intheplacebogroup,resultinginatreatmentdifferenceof–0.54%(P<0.001).TheLSmeanpercentchangeinLDLcholesterolfrombaselinetoweek26was–16.1%inthecolesevelamgroupand+0.6%intheplacebogroup,resultinginatreatmentdifferenceof–16.7%(P<0.001).FurThermore,significantreductionsinfastingplasmaglucose,fructosamine,totalcholesterol,non–HDLcholesterol,andapolipoproteinBweredemonstratedinthecolesevelamrelativetoplacebogroupatweek26.
CONCLUSIONS—ColesevelamimprovedglycemiccontrolandreducedLDLcholesterollevelsinpatientswithtype2diabetesreceivingsulfonylurea-basedtherapy.
暂无品牌问答